What Is Rosuvastatin's Intermediate Metabolite?
Rosuvastatin, sold as Crestor, undergoes limited metabolism in the liver, primarily via CYP2C9 to an N-desmethyl intermediate metabolite. This metabolite retains about 40-50% of the parent drug's HMG-CoA reductase inhibitory activity, contributing to overall cholesterol-lowering effects without dominating efficacy.[1][2]
How Does This Affect Overall Efficacy?
The intermediate's partial activity means rosuvastatin's potency relies mostly on the unchanged drug, which has high bioavailability (around 20%) and a long half-life (19 hours). Unlike statins like simvastatin that produce more active metabolites, rosuvastatin's minor intermediate role results in predictable pharmacokinetics and fewer drug interactions, supporting consistent LDL-C reduction of 40-60% at standard doses.[1][3]
Comparison to Other Statins' Metabolites
- Simvastatin and lovastatin: Active metabolites (e.g., simvastatin acid) amplify efficacy but increase CYP3A4 interaction risks.
- Atorvastatin: Major active metabolites extend duration but complicate dosing in liver impairment.
- Pravastatin: Minimal metabolism, similar to rosuvastatin, for direct efficacy.
Rosuvastatin's weaker intermediate minimizes variability, making it effective across genotypes like CYP2C9 poor metabolizers.[2][4]
Does the Intermediate Raise Safety Concerns?
Low metabolite activity reduces active drug accumulation risks in renal/hepatic impairment, but slight increases occur in Asian patients due to slower clearance (higher AUC by 2-fold). No major efficacy loss, though dose adjustments (max 10mg) prevent myopathy.[1][5]
Clinical Evidence on Efficacy Impact
Trials like JUPITER showed rosuvastatin 20mg reduced major cardiovascular events by 44%, attributed to high parent drug potency over metabolite contribution. PK studies confirm the intermediate adds ~10-20% to total inhibition, not altering dose-response curves significantly.[3][6]
[1]: FDA Crestor Label
[2]: DrugPatentWatch.com - Rosuvastatin Patents & Metabolism
[3]: Martin PD et al. Clin Pharmacol Ther. 2003;73(1):8-20.
[4]: Prueksaritanont T et al. Drug Metab Dispos. 2002;30(11):1158-63.
[5]: FDA Rosuvastatin Asian Bridging Study.
[6]: Ridker PM et al. NEJM. 2008;359(21):2195-207.